FDA Recalls Lay's Potato Chips Over ‘Class I' Risk
Here is the detailed article.
FDA's Lay's Potato Chips recall as 'Class I' risk putting the brand's credibility at risk. As per reports, the Lay's Potato Chips recall started when Frito-Lay revealed that over 6,000 bags of Lay's Classic Potato Chips found in Oregon and Washington contained undeclared milk.
As per the FDA, the existence of undeclared milk in Lay's Potato Chips poses life-threatening risks for those who have any milk allergy. For the unversed, an FDA Recall is a 'voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective.'
Highlighting the importance of food recall, the FDA said on December 16, 'Those with an allergy or severe sensitivity to milk run the risk of a serious or life-threatening allergic reaction if they consume the recalled product.'
Undisclosed food ingredients can cause harmful reactions for people suffering from food allergies. Some of the most common undisclosed allergens found in foods include milk, peanuts, and shellfish.
A Food Allergy Research & Education (FARE) survey notes that almost 33 million Americans suffer from one or multiple types of food allergies. Additionally, over 40% of children in the U.S. have faced severe food allergic reactions.
Experts believe that allergen-free certifications for many store-bought food items could be helpful for the sensitive population suffering from any sort of food allergy. According to FARE, the food allergy epidemic is on the rise, so the need for allergen-free certifications is more than ever, not just in the United States but globally.
Originally reported by Arpita Adhya on ComingSoon.net.
The post FDA Recalls Lay's Potato Chips Over 'Class I' Risk appeared first on Mandatory.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
10 minutes ago
- The Hill
Tennessee school won't accept doctor's notes for absences
(NewsNation) — One Tennessee school district will no longer accept doctors' notes to excuse an absence despite objections from parents. Lawrence County School System officials said the school is instituting the policy to teach students work ethic and reliability, saying that students will be expected to go to work sick or injured as adults. It is also intended to address chronic absenteeism, defined as missing 10 percent or more of instructional time. In the 2023-2024 school year, Lawrence County had a 14 percent rate of chronic absenteeism. With no federally mandated sick leave, many Americans do go to work when sick, but public health officials advise against it. Staying home when sick can reduce the spread of viruses like the flu and COVID-19 and protect vulnerable people in the community. The new attendance policy says students will simply be marked absent or present, with no options for doctors to verify a child is absent because they are sick or injured, need to stay home to recover or to prevent spreading contagious illnesses to their classmates. The policy is meant to help improve attendance rates, but parents have objected, noting that an absence for an illness like the flu could now mean a referral to the Lawrence County Juvenile Court for truancy. Children who get sick at school or are sent to school sick and sent home by a nurse will be counted as tardy. Three tardies will equal an absence. The new policy also says schools will start intervention after just three days, and eight or more days marked absent will result in a court referral. Other penalties could include failing a class or grade, not being allowed to participate in graduation or get a driver's license or permit. There will be exemptions for students with documented chronic illnesses and emergencies out of the student's control, as well as allowances for deaths in the family and some religious observances. The school district sent a letter to medical providers asking them to emphasize regular school attendance and warning that medical notes could imply students should stay home even after their health improves.
Yahoo
27 minutes ago
- Yahoo
What will Trump's new homelessness executive order mean for California?
An executive action taken by President Donald Trump on Thursday, aiming to push cities and states to remove homeless people from the streets, could make California governments' ability to secure Federal funding contingent on taking such steps and changing the state's current approach to homelessness. Trump signed an order directing Attorney General Pam Bondi to seek to reverse federal and state judicial precedents and end consent decrees that limit local and state governments' ability to move homeless people from streets and encampments into treatment centers. The move, first reported by USA TODAY, also redirects federal funds to ensure the homeless people impacted are transferred to rehabilitation, treatment, and other facilities, though it was unclear how much money would be allocated. Here's what to know about Trump's executive order on removing homeless people from the streets. More: In major decision, Supreme Court allows cities to ban homeless camps What did Trump's executive order say? Under the order ‒ which the White House has titled "Ending Crime and Disorder on America's Streets" ‒ Bondi is also required to work with the secretaries of Health and Human Services, Housing and Urban Development and Transportation to prioritize federal grants to states and cities that "enforce prohibitions on open illicit drug use, urban camping and loitering, and urban squatting, and track the location of sex offenders." White House press secretary Karoline Leavitt, in a statement to USA TODAY, said Trump is "delivering on his commitment to Make America Safe Again and end homelessness across America." "By removing vagrant criminals from our streets and redirecting resources toward substance abuse programs, the Trump Administration will ensure that Americans feel safe in their own communities and that individuals suffering from addiction or mental health struggles are able to get the help they need," Leavitt said. More: The average American is closer to being homeless than being Elon Musk What order may mean for California In recent years, California has become a national poster child for the issue of homelessness, the challenges it poses and the difficulty governments can have with meaningfully addressing it. The US Senate Housing Committee reported earlier this year that a recent homeless count found that just over 187,000 people were homeless in California. That represented a 3% increase from the year before, less than the 18% increase observed nationwide. But it was still the highest homeless population of any state and accounted for 28% of the homeless people in America, while the state makes up just 11.7% of the population. The report also said that 66% of homeless people were "unsheltered," the highest percentage in the nation. In recent years, California Gov. Gavin Newsom has made several efforts to help — and, increasingly, push — cities in the state to address issues with homelessness and people living without shelter. In 2023, the state made $1 billion in funding available through grants to communities to address homelessness. A year later, urged cities to take action to make homeless encampments illegal in their cities and take action to move people off their streets and provide them with shelter and services. Earlier this year, he released a "model ordinance" that he encouraged cities to use as a template for passing their own laws banning camping in their cities. "There's nothing compassionate about letting people die on the streets," Newsom said in a statement he issued at the time he released the model ordinance. "Local leaders asked for resources — we delivered the largest state investment in history. They asked for legal clarity — the courts delivered. Now, we're giving them a model they can put to work immediately, with urgency and with humanity, to resolve encampments and connect people to shelter, housing, and care." Trump's order pushes for many of the same approaches and aims Newsom has advocated for, while making the government's eligibility for Federal grant money contingent on communities taking steps to get people off the street and into treatment and showing success in doing so. The order says that eligibility for grants will be based on cities and states' ending "housing first" policies. Such policies emphasize an approach to addressing homelessness focused on getting unhoused people into permanent housing as a first step to successfully transitioning them out of homelessness. All California housing programs have been required to adopt a "housing-first" model since 2016, with a bill that would've ended that requirement failing to advance out of committee earlier this year. On Thursday, a spokesperson for Newsom criticized the order to KQED, saying it was based on "harmful stereotypes and ineffective policy" in comparison to Newsom's executive order on encampments that she said had been based on the law and facts. But she also said that Trump's imitation of Newsom (even poorly executed) is the highest form of flattery. Trump's action follows major Supreme Court decision on homeless camps Trump's action comes after the Supreme Court ruled in June 2024 that that people without homes can be arrested and fined for sleeping in public spaces, overturning a lower court's ruling that enforcing camping bans when shelter is lacking is cruel and unusual punishment. The 6-3 decision, split among ideological lines in the conservative-majority court, upheld a ban in Grant Pass, Oregon, prohibiting homeless residents from sleeping outdoors. Homeless residents of the southern Oregon city of 38,000 face fines starting at $250 and jail time for repeat offenses. More: Homelessness rates jumped by double digits in 2024 as Americans battled to afford housing In a statement, the National Homelessness Law Center condemned Trump's order, characterizing it as misguided at best, and counterproductive and dangerous at worst. "The safest communities are those with the most housing and resources, not those that make it a crime to be poor or sick," said Jesse Rabinowitz of the National Homelessness Law Center. 'As a licensed mental health professional, I know that forced treatment is unethical, ineffective, and illegal." "People need stable housing and access to healthcare," Rabinowitz said. Rather, Trump's actions will force more people into homelessness, divert taxpayer money away from people in need, and make it harder for local communities to solve homelessness." Across the U.S., more than 771,800 people lived without housing in 2024, according to a HUD count taken annually on a single night in January. It was the highest tally ever recorded, a 18.1% jump than in 2023, when officials counted about 650,000 people living in homeless shelters or in parks and on streets. Many cities have struggled to build more affordable housing in recent years, while some communities have pushed for harsher laws banning tents and sleeping in public spaces. More: The homeless population is increasing. Will Trump's second term make it worse? Trump has often expressed his distaste of homeless camps, singling out the removal of encampments on parks and federal land in Washington as a priority. Trump, in a 2023 campaign video, said: "We will use every tool, lever, and authority to get the homeless off our streets. We want to take care of them, but they have to be off our streets.' Other items in Trump's order include language that seeks to ensure that grants intended for substance use disorder prevention and recovery don't fund drug injection sites or illicit drug use. The order also prohibits convicted sex offenders who receive homelessness assistance from being housed with children and supports new homeless programs to exclusively house women and children. Reach Joey Garrison on X @joeygarrison. Paul Albani-Burgio covers growth, development and business in the Coachella Valley. Email him at This article originally appeared on Palm Springs Desert Sun: How Trump homelessness order could impact California Solve the daily Crossword
Yahoo
35 minutes ago
- Yahoo
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
CAMBRIDGE, Mass., July 25, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement* Death was reported to health authorities* Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl)ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS:Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking StatementsThis statement contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading "Risk Factors" in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc. View source version on Contacts Investor Contact: Ian Estepan617-274-4052iestepan@ Media Contacts: Tracy Sorrentino617-301-8566tsorrentino@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
